“To assist this process and to support the Reference Committee’s tight schedule, Medicines Australia has collaborated with members and stakeholders to develop a first draft set of recommended terms of reference for the HTA Reform," said CEO Liz de Somer.
Medicines Australia issues 'conversation starter' for HTA review
June 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
BMS therapy secures Australian approval for psoriatic arthritis
September 3, 2026 - -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - -
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech
